Blog - Pharmaceutical Products

GlaxoSmithKline's Promising Outlook Amid Concerns

Feb 11, 2025

GlaxoSmithKline (GSK) unveils a promising 2025 outlook with strategic initiatives in drug development and a £2 billion share buyback plan, despite challenges in vaccine sales.

Novartis Acquires Anthos Therapeutics in Major Deal

Feb 11, 2025

Novartis's acquisition of Anthos Therapeutics strengthens its position in the anticoagulant market, promising innovative cardiovascular solutions.

Vertex Pharmaceuticals Sees Promising Growth with CF Treatments and New Pain Drug

Feb 10, 2025

130

Vertex Pharmaceuticals projects a notable revenue increase by leveraging its cystic fibrosis treatments and new pain management medication, Journavx, with plans for future growth.

Merck KGaA Eyes Major Acquisition in Oncology Sector

Feb 10, 2025

202

Merck KGaA is in advanced talks to acquire Springworks Therapeutics, aiming to enhance its oncology portfolio amid renewed healthcare transaction activity.

United States Sees Significant Drop in Human and Animal Blood Exports, Slashing Value to $3.5 Billion by 2024

Feb 10, 2025

In the period of 2018 to 2024, the growth of exports for Human And Animal Blood failed to regain momentum. The value of exports declined to $3.5B in 2024.

Incyte Corporation Set to Announce Quarterly Earnings

Feb 9, 2025

541

Discover Incyte Corporation's projected quarterly earnings with a 12.9% revenue growth, aligned with industry trends and analyst forecasts.

In 2024, the Netherlands Sees a Rise in Biological Product Exports, Reaching $20.5 Billion

Feb 8, 2025

During the review period, Biological Product exports peaked at 27K tons in 2021 before slightly decreasing from 2022 to 2024. The total value of these exports reached $20.5B in 2024.

Eli Lilly Exceeds Earnings Expectations, Ups 2025 Guidance

Feb 6, 2025

Eli Lilly reports strong Q4 2024 earnings, boosts 2025 guidance; driven by impressive GLP-1 drug sales, it remains an attractive investment opportunity.

Bristol Myers Squibb Predicts Revenue Drop by 2025 Due to Generic Drugs

Feb 6, 2025

Bristol Myers Squibb faces upcoming revenue challenges by 2025 due to generic competition and patent losses, impacting its financial outlook.

Bain Capital Approaches Acquisition of Mitsubishi's Pharma Arm

Feb 6, 2025

163

Bain Capital is on the verge of acquiring Mitsubishi Chemical's pharmaceutical division, valued at $3.3 billion, marking a significant step in Japan's pharmaceutical sector.

Eli Lilly Strives to Boost Zepbound Sales Despite Supply Chain Challenges

Feb 5, 2025

149

Eli Lilly is strategizing to increase Zepbound sales as they face supply chain difficulties, impacting their revenue outlook.

Novo Nordisk Faces Slower Sales Growth Amidst Increased Competition

Feb 5, 2025

Novo Nordisk projects slower sales growth in 2025 due to competition from Eli Lilly, with plans to enhance commercial strategies and expand production.